Altimmune (ALT) Non Operating Investment Income (2017 - 2018)
Altimmune (ALT) posted quarterly Non Operating Investment Income of $806224.0 for Q3 2018, up 258.61% year-over-year from $224821.1 in Q3 2017, and up 149.29% quarter-over-quarter from -$1.6 million in Q2 2018.
Powered by 
Analysis
Altimmune (ALT) Non Operating Investment Income (2017 - 2018) Analysis & Trends
Altimmune (ALT) has reported Non Operating Investment Income for 2 consecutive years, with $806224.0 the latest figure, recorded in Q3 2018.
- In Q3 2018, Non Operating Investment Income rose 258.61% year-over-year to $806224.0; the TTM figure through Sep 2018 stood at $1.3 million (changed N/A YoY), while the FY2017 annual figure was $97763.0, changed N/A from the prior year.
- Non Operating Investment Income climbed to $806224.0 in Q3 2018 per ALT's latest filing, from -$1.6 million in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $1.5 million in Q1 2018 and bottomed at -$1.6 million in Q2 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | Altimmune | 618.45 Mn | 618.45 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2018 | 806,224.00 |
| Jun 30, 2018 | -5.23 Mn |
| Mar 31, 2018 | 1.55 Mn |
| Dec 31, 2017 | 606,079.00 |
| Sep 30, 2017 | -508,316.00 |